UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041214
Receipt number R000047069
Scientific Title Comparison of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block for analgesic effect and motor function
Date of disclosure of the study information 2020/07/27
Last modified on 2020/07/27 13:03:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block for analgesic effect and motor function

Acronym

Comparison of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block for analgesic effect and motor function

Scientific Title

Comparison of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block for analgesic effect and motor function

Scientific Title:Acronym

Comparison of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block for analgesic effect and motor function

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Anesthesiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the analgesic effect and motor function of 0.25% levobupivacaine 10 ml or 0.125% levobupivacaine 10 ml for Interscalene Brachial Plexus Block.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Motor function and pain within 1 hour after surgery and analgesic duration

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

In surgery of the shoulder or upper arm, brachial plexus block is performed by the interscalene method after induction of anesthesia. At that time, 10 ml of 0.25% levobupivacaine is used as the drug.

Interventions/Control_2

In surgery of the shoulder or upper arm, brachial plexus block is performed by the interscalene method after induction of anesthesia. At that time, 10 ml of 0.125% levobupivacaine is used as the drug.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients scheduled for surgery on shoulder or upper arm

Key exclusion criteria

Patients who are taking antipsychotics, patients with mental illness, severe obesity (BMI 35 or higher), patients with chronic pain, patients who are taking opioids and analgesics, patients with dementia, and those who refuse to participate.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Hayato
Middle name
Last name Terashima

Organization

National Defense Medical College

Division name

Department of Anesthesiology

Zip code

359-0513

Address

3-2 Namiki Tokorozawa Sitama

TEL

04-2995-1211

Email

doc33043@ndmc.ac.jp


Public contact

Name of contact person

1st name Hayato
Middle name
Last name Terashima

Organization

National Defense Medical College

Division name

Department of Anesthesiology

Zip code

359-0513

Address

3-2 Namiki Tokorozawa Sitama

TEL

04-2995-1211

Homepage URL


Email

doc33043@ndmc.ac.jp


Sponsor or person

Institute

National Defense Medical College

Institute

Department

Personal name



Funding Source

Organization

National Defense Medical College

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Defense Medical College

Address

3-2 Namiki Tokorozawa Sitama

Tel

04-2995-1211

Email

doc33043@ndmc.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2020 Year 07 Month 27 Day

Date of IRB


Anticipated trial start date

2020 Year 07 Month 27 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 07 Month 27 Day

Last modified on

2020 Year 07 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047069


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name